At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|November 22, 2022
Dr. Lowentritt highlights LUGPA discussion on urologic care for LGBTQ patients
Author(s)Urology Times staff
“From a patient care standpoint, anything that opens the door and makes the patient feel more secure and open is going to lead to better outcomes for them and allow us to serve their needs best,” says Benjamin Lowentritt, MD, FACS.
Advertisement
In this interview, Benjamin Lowentritt, MD, FACS, highlights key takeaways from the discussion “Appreciating Diversity in Urology Care”, which took place during the
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
How PSMA-PET shapes staging and recurrence workup in prostate cancer
3
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5